Article
Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC.
BMC medicine - 19 Oct 2021
Zhang Yongchang, Zeng Liang, Zhang Xiangyu, Li Yizhi, Liu Lingli, Xu Qinqin, Yang Haiyan, Jiang Wenjuan, Lizaso Analyn, Qiu Luting, Hou Ting, Liu Jun, Peng Ling, Yang Nong
Abstract excerpt
BACKGROUND: The combination of bevacizumab and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) could prolong progression-free survival (PFS) in patients with EGFR-mutant advanced non-small-cell lung cancer (NSCLC). Our study investigated the clinical and molecular factors that affect the efficacy of first-generation EGFR-TKI with or without bevacizumab and identify the subset of patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.